The findings indicate that a patient-centred approach which explores BAM before a consultation can help tailor the discussion to better meet patient's needs and establish medicines partnership. This can potentially improve adherence.
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Underuse of recommended secondary preventive therapies in current routine clinical practice Aims: Recommendations on the use of antithrombotic agents, antihypertensive drugs and statin for secondary prevention of coronary artery (CAD), ischemic cerebrovacular (CVD), and peripheral arterial (PAD) diseases are now well established. However, there may be a gap between clinical practice and evidencebased guidelines. We aimed to investigate the premorbid use of secondary prevention medications in patients with recurrent cardiovascular events.
Methods and results:
We prospectively recorded all patients with CVD and CAD in Dijon, France from 2006 to 2010. Data about medical history and prior use of treatments were collected. Mutivariate analyses were performed to identify predictors of the use of medications in patients with previous cardiovascular disease. Among the 2126 patients included (1270 CVD and 856 CAD), 867 (40.8%) had a history of cardiovascular diseases including 448 (51.7%) with prior CVD only, 191 (22.0%) with prior CAD only, 68 (7.8%) with prior PAD only, and 160 (18.5%) with polyvascular disease. In these patients, 57.3% were on antithrombotic therapy, 61.2% were treated with antihypertensive drugs, 32.9% received statins, and only 23.6% were on an optimal regimen, defined as the combination of the three therapies. Compared with patients with previous CAD only, those with previous CVD only were less likely to be receiving each of these treatments or to receive an optimal regimen (OR=0.17, p<0.001). Conclusion: This study highlighted the underuse of recommended secondary preventive therapies in current clinical practice. Underuse was particularly pronounced in patients with previous CVD. These findings may account for the burden of recurrent events. Purpose: To assess time trends in the use of main drug classes for secondary prevention, during hospitalization and at hospital discharge, following an ACS, in Portugal, using a systematic review. Methods: We searched PubMed, from inception until 2012, to identify studies reporting the proportion of ACS patients treated with aspirin, clopidogrel, betablockers, angiotensin-converting enzyme (ACE) inhibitors and statins. We used linear regression to quantify the annual variation in use of drugs, adjusting for the proportion of men in the sample and patients' mean age, and including a quadratic term of data collection year when relevant.
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Results:
In 25 eligible studies, including patients treated from 1993 to 2009, we observed an increase in the prescription of pharmacological treatments at hospital discharge. The use of pharmacological therapy for secondary prevention prescribed at hospital discharge, according to year of data collection is illustrated in the Figure. Extrapolating from these data, and assuming a mean patient age of 65 years and 70% of men, we estimate that, in 2008, 95% of patients would have been discharged with aspirin, 92% with clopidogrel, 82% with beta-blockers, 80% with ACE inhibitors and 91% with statins. Treatment during hospitalization followed a similar pattern, except for a steeper increase in ACE inhibitors use, which was initially lower, but reached similar levels to those at discharge in recent years.
Therapy at hospital discharge Conclusions: In Portugal, there was an increase in the use of recommended pharmacological therapy for secondary prevention after an ACS over the last 15 years, during hospitalization and at hospital discharge.
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Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study 
